PAGE '95: ABSTRACT LIST

• Contents
• 1 Practical Experience and Issues in Designing and Performing Population Pharmacokinetic/Pharmacodynamic Studies
• 2 Stochastic model in the analysis of migrain data
• 3 Determination of the Population Pharmacokinetics of Bismuth from GR122311X in Healthy Volunteers using the Gibbs Sampler Bayesian Method.
• 4 Non Linear Pharmacokinetics of Ethanol. Analysis of Patients with NONMEM. Study I
• 5 Non Linear Pharmacokinetics of Ethanol. Population Model with NONMEM After an Optimal Sampling Duration. Study II
• 6 Population of Vancomycine with Continuous Infusion Administered in Neutropenic Patients Modeling on NPEM2-NONMEM-P-PHARM
• 7 Sufentanyl Pharmacokinetic-Pharmacodynamic Modelling (PK/PD) on NONMEM in 10 Patients with Coronary Surgery
• 8 Population Distribution of Platinum Pharmacokinetic Parameters for Dosage Recommendations of CDDP and Adaptive Control during the Course of Therapy, using different Softwares.
• 9 Population Pharmacokinetics of Tacrolimus in Liver Transplant Patients
• 10 A Prospective Evaluation of Sparse Sampling for Toxicokinetics in the Course of Drug Development.
• 11 How Many Patients and Blood Levels for Population Pharmacokinetic Analysis? a Study with a One Compartment Model.
• 12 From Animal to Man
• 13 Effect Concentration Relationships of Theophylline in Apnoea of Prematurity
• 14 Sampling Strategies for Population Analysis: a Theoretical Study to Support Practical Results Obtained with Caffeine in Premature Neonates
• 15 Pharmacokinetic/-Dynamic Modeling of a Bivariate Control System: Luteinizing Hormone and Testosterone Response to GnRH Antagonist Antide
• 16 Population Approach to Nonlinear Pharmacokinetics of a New Drug under Development
• 17 Relationship Between the Pharmacokinetics and the Pharmacodynamics of Taxotere (RP56976, DOCETAXEL) in Cancer Patients
• 18 Population Pharmacokinetics: Effect of Sampling Scheme on Parameter Estimation.
• 19 Discrimination between Rival Dosing Histories
• 20 Determination of Relative Potency for Drug and Metabolite in Vivo
• 21 Population Kinetics and Individual Drug Dosage Adjustment
• 22 Population Pharmacokinetic-Pharmacodynamic of a New Specific Bradycardic Agent: S-16257
• 23 The use of Population Pharmacokinetic Approaches to Aid in the Assessment of Bioequivalence for a Highly Variable Drug
• 24 NONMEM in Destructive Sampling Experiments; Experiences with the Toxicokinetics of Dibromchloromethane
• 25 Prediction of Simvastatin Pharmacological Response: A Population Analysis
• 26 Apache II as Predictor of Gentamicin Pharmacokinetic Parameters in Critical Ill Patients
• 27 Population Pharmacokinetics Analysis of Mizolastine: Estimation with NPML and Validation
• 28 High Variability Compounds - High Risk for Developers?
• 29 Modeling Interoccasion Variability in Toxicokinetics and Toxicodynamics
• 30 A Population Approach to Predicting Post-Treatment Levels of Epirubicin in Patients with Advanced Breast Cancer
• 31 Performance Evaluation of Three Softwares for Bayesian Predictions of Teicoplanin Pharmacokinetic Parameters: APIS MICROPHARM, PKS Abbott
• 32 Influence of Apomorphine on the PK/PD-Relationship of Levodopa: Two-Step versus NONMEM Analysis
• 33 An Industrial Perspective: Practical Stages in Model Development
• 34 Lack of Relationship between Systemic Exposure for the Component Drugs of the FEC Regimen in Breast Cancer Patients
• 35 Carbamazepine Population Pharmacokinetics in Children
• 36 Estimation of Kinetic/Dynamic Curves With Insufficient Information for Each Individual Using Non-Linear Mixed Effect Modelling
• 37 An Algorithm for the Estimation of Optimal Sampling Times in Pharmacokinetics by the ED, EID and API Criteria
• 38 A Population Pharmacokinetic Study of Isepamicin in ICU Patients
• 39 Population Pharmacokinetics of Intravenous Melphalan: NONMEM and MP2 Analysis
• 40 MP2 (MicroPharm Population): A Windows Application for Population Pharmacokinetics
• 41 A Population Approach Enables the Characterisation of Saturable Protein Binding for Ropivacaine
• 42 Bayesian Individualization via Sampling-Based Methods.
• 43 Software product POPKAN; Population pharmacokinetic modelling and analysis
• 44 Optimization of a ''First Dose in Man'' Study using a NONMEM Model for Mammals
• 45 New Evidence for a Triexponential Disposition of Cefotaxime
• About this document ...